After multiple hearings on 340B reform in both the US House and Senate over the past two years, there is evident interest among Republicans and the Trump Administration in moving legislation requiring health care providers to report back to the federal government on how they are using the savings from 340B prescription drug discounts.
The concept has been supported by the leadership of the Senate Health, Education, Labor and Pensions Committee, which held its...







